Ana Verma

Ana Verma

Auto-generated profile, based on publicly available information

Ana Verma

Laboratory of Systems Pharmacology, Department of Systems Biology, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2022 in Science
Verified
Journal Article
Closed access
PTPeter Tsvetkov
Peter Tsvetkov
SCShannon Coy
Shannon Coy
Boryana PetrovaBoryana Petrova
Boryana Petrova
MDMargaret Dreishpoon
Margaret Dreishpoon
AVAna Verma
Ana Verma
TGTodd R. Golub
Todd R. Golub
Copper is an essential cofactor for all organisms, and yet it becomes toxic if concentrations exceed a threshold maintained by evolutionarily conserved homeostatic mechanisms. How excess copper induces cell death, however, is unknown. Here, we show in human cells that copper-dependent, regulated cell death is distinct from known death mechanisms and is dependent on mitochondrial respiration. We show that copper-dependent death occurs by means of direct binding of copper to lipoylated components of the tricarboxylic acid (TCA) cycle. This results in lipoylated protein aggregation and subsequent iron-sulfur cluster protein loss, which leads to proteotoxic stress and ultimately cell death. These findings may explain the need for ancient copper homeostatic mechanisms.

1 September 2021 in Cell
Verified
Journal Article
Closed access
KKKazuhiro Koikawa
Kazuhiro Koikawa
SKShin Kibe
Shin Kibe
FSFutoshi Suizu
Futoshi Suizu
NSNobufumi Sekino
Nobufumi Sekino
NKNami Kim
Nami Kim
KLKun Ping Lu
Kun Ping Lu

15 March 2022 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
GGGiorgio Gaglia
Giorgio Gaglia
SKSheheryar Kabraji
Sheheryar Kabraji
DRDanae Rammos
Danae Rammos
YDYang Dai
Yang Dai
AVAna Verma
Ana Verma
SSSandro Santagata
Sandro Santagata

10 October 2025 in JHEP Reports
Verified
Journal Article
Open access
JCJonggi Choi
Jonggi Choi
AVAna Verma
Ana Verma
VNVy H. Nguyen
Vy H. Nguyen
EPEric Przybyszewski
Eric Przybyszewski
JSJiunn Song
Jiunn Song
RCRaymond T. Chung
Raymond T. Chung
The comparative effectiveness of antidiabetic therapies on hepatic outcomes in patients with type 2 diabetes mellitus (T2DM) is not well established. We conducted a retrospective new-user cohort study emulating a target trial using electronic health records from the Mass General Brigham health system (USA) between January 2012 and June 2024. Adults with T2DM who newly initiated sodium-glucose cotransporter-2 inhibitors (SGLT2is), glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP4is), or sulfonylureas were included. Propensity scores were estimated using prespecified clinical and high-dimensional covariates, and overlap weighting was applied to achieve covariate balance. Among 38,524 eligible patients, 12,344 initiated GLP-1RAs, 5,233 SGLT2is, 3,717 DPP4is, and 17,230 sulfonylureas. Over a median follow-up of 3.1 years, 1,743 hepatic decompensation events occurred. In the intention-to-treat analysis, GLP-1RAs (hazard ratio [HR] 0.58, 95% CI 0.38–0.88) and SGLT2is (HR 0.65, 95% CI 0.43–0.98) were associated with significantly lower risk compared with sulfonylureas. Pairwise analyses also showed reduced risk with GLP-1RAs (HR 0.59, 95% CI 0.39–0.89) and SGLT2is (HR 0.66, 95% CI 0.43–1.00) compared with DPP4is, with no significant difference between GLP-1RAs and SGLT2is. In the per-protocol analysis (1,151 events), GLP-1RAs (HR 0.43, 95% CI 0.22–0.82) remained strongly protective, while SGLT2is showed a trend toward reduced risk (HR 0.61, 95% CI 0.33–1.12). Sensitivity analyses excluding early events or using alternative weighting approaches produced consistent results. In patients with T2DM, initiation of GLP-1RAs or SGLT2is was associated with substantially lower risk of hepatic decompensation compared with sulfonylureas and DPP4is. These findings support their preferential use in clinical practice. This study provides robust real-world evidence on the comparative effectiveness of four major antidiabetic drug classes in reducing hepatic decompensation among patients with type 2 diabetes mellitus. Our findings suggest that glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors are associated with substantially lower risk of hepatic decompensation compared with sulfonylureas and dipeptidyl peptidase-4 inhibitors, supporting their preferential use in patients with coexisting diabetes and liver disease risk. These results are particularly relevant for clinicians managing patients with type 2 diabetes who may have unrecognized metabolic dysfunction-associated steatotic liver disease or other chronic liver diseases. In practice, these findings can help guide therapeutic decision-making by integrating liver-related outcomes into antidiabetic drug selection. However, future prospective studies are needed to validate these findings and clarify the mechanisms underlying the observed benefits.